Can Lurbinectedin be covered by medical insurance for small cell lung cancer?

Lurbinectedin (Lurbinectedin) is currently not reimbursable by medical insurance for patients with small cell lung cancer. Because Rubicatin has not been approved by the National Medical Products Administration and has not been included in the national medical insurance, it cannot be reimbursed through medical insurance. However, the country is gradually taking various measures to reduce the prices of targeted drugs that are urgently needed by patients. In the future, more drugs with clinical value and urgent needs for treatment may be included in the scope of medical insurance. Rubicatin is a targeted drug with a specific mechanism of action. It is mainly used for two specific types of cancer: recurrent small cell lung cancer (SCLC) and recurrent synovial sarcoma (Myxoid/round cell liposarcoma).